First-line biologic treatment of inflammatory bowel disease during the first 12 months after diagnosis from 2010 to 2016: a Norwegian nationwide registry study-Reference-Cited by-同舟云学术

First-line biologic treatment of inflammatory bowel disease during the first 12 months after diagnosis from 2010 to 2016: a Norwegian nationwide registry study

Published:2021-07-28 Issue:10 Volume:56 Page:1163-1168
ISSN:0036-5521
Container-title:Scandinavian Journal of Gastroenterology
language:en
Short-container-title:Scandinavian Journal of Gastroenterology

Author:

Anisdahl Karoline¹²^ORCID,Svatun Lirhus Sandre³^ORCID,Medhus Asle W.¹^ORCID,Moum Bjørn¹²^ORCID,Melberg Hans Olav³,Høivik Marte Lie¹²^ORCID

Affiliation:

1. Department of Gastroenterology, Oslo University Hospital, Oslo, Norway

2. Institute of Clinical Medicine, University of Oslo, Oslo, Norway

3. Department of Health Management and Health Economics, University of Oslo, Oslo, Norway

Funder

Takeda AS

Publisher

Informa UK Limited

Subject

Gastroenterology

Link

https://www.tandfonline.com/doi/pdf/10.1080/00365521.2021.1955147

Reference25 articles.

1. Infliximab for the Treatment of Fistulas in Patients with Crohn's Disease

2. Infliximab Maintenance Therapy for Fistulizing Crohn's Disease

3. Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis

4. Access to biologicals in Crohn’s disease in ten European countries

5. Regional differences in anti-TNF-α therapy and surgery in the treatment of inflammatory bowel disease patients: a Norwegian nationwide cohort study

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Frailty risk and treatment strategy in elderly-onset inflammatory bowel disease. A Norwegian nationwide population-based registry study;Digestive and Liver Disease;2024-09

2. Biosimilars and access to biologic therapy in immune-mediated diseases;Expert Opinion on Biological Therapy;2024-05-14

3. Subcutaneous Vedolizumab Treatment in a Real-World Inflammatory Bowel Disease Cohort Switched From Intravenous Vedolizumab: Eighteen-Month Prospective Follow-up Study;Crohn's & Colitis 360;2024-01-01

4. Cardiovascular Manifestations in Inflammatory Bowel Disease;Current Cardiology Reviews;2023-11-24

5. The cost of inflammatory bowel disease in high-income settings: a Lancet Gastroenterology & Hepatology Commission;The Lancet Gastroenterology & Hepatology;2023-05